LONGEVA.

B7-33: adverse events and evidence limits

B7-33 is a single-chain relaxin analogue. Hossain and colleagues tested prostate-tumour effects in mice: six animals in each of two B7-33 groups, receiving eight-day subcutaneous pump infusions. The authors found no exacerbation of tumour growth versus control. [1]

That experiment measured tumour size in one model. It establishes neither cancer safety nor human adverse-reaction frequencies for B7-33; findings about full-length relaxin cannot automatically be transferred to this analogue. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Exacerbation of prostate tumour growthMice, six animals in each of two B7-33 groups, eight-day subcutaneous pump infusionNot found versus control; the experiment does not establish human adverse-reaction frequencies[1]

References

  1. Hossain MA, Kocan M, Yao ST, Royce SG, Nair VB, Siwek C, Patil NA, Harrison IP, Rosengren KJ, Selemidis S, Summers RJ, Wade JD, Bathgate RAD, Samuel CS. (2016). A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1 https://doi.org/10.1039/C5SC04754D.